|Yes I agree -very thorough.|
|Yes. He's good, got me into pv crystalox...|
|Very good analysis here:hxxp://alphavulture.com/2016/10/20/beximco-pharma-reports-results-for-the-first-half-of-2016/|
|Anyone checked out the results?|
|Breaking out again?|
|Dividend confirmed. Nice set of numbers there...|
|Nice bit of volume today. Any news?|
|"The AGM will now be held before the end of this calendar year and will consider, inter alia, the adoption of the Company's audited report and accounts for the 18 month period ending on 30 June 2016, which is the new financial year end of the Company."|
|The 5% Stock dividend will be issued subject to the approval of the shareholders at the forthcoming Aim... So, when's the agm?|
|Following the AGM to be held before year end we should receive the usual 5% scrip dividend though.|
|The dividend was a month or two ago
|Right, had a little nibble here. I presume I'm too late for the dividend...|
|Yes I realise the two quotes are independent of one another but logically it must follow that one day the two will coincide.|
|Did you mean the stock dividend of 5 per cent.Sharpish post 1091? The Dhaka parent stock is not fungible with the London GDR listing Dave Bowler. Only sentiment drives this IE that sterling is weak and this a holding in a good company - the flagship of their country.Sure you would have known - maybe slipped the memory.The dividends though benefit from sterling weakness but we are only down about 14 per cent due to the inflation in Bangladesh|
|Fantastic. I only bought in to these after listening to Evil Kinevil speak at one of the Investor shows, years ago. Glad I held on all these years.
|Beximco quote on the Dhaka Stock market -HTtp://www.dsebd.org/displayCompany.php?name=BXPHARMA -currently 86 Taka
There are about 100 Taka to the £ HTtp://www.xe.com/currencycharts/?from=GBP&to=BDT&view=1D so the UK price is way down on the Dhaka one.
Plenty to go!|
|Pretty incredible performance so far today and still a long way off parity with home market. Hopefully new investors take notice, US market entry gives so much credibility/opportunity.|
|RNS Number : 3255G
Beximco Pharmaceuticals Ltd
05 August 2016
5 August 2016
BEXIMCO PHARMACEUTICALS LTD.
Beximco Pharma commences export to the United States
First Bangladeshi pharmaceutical company to launch pharmaceutical products in the US
Beximco Pharmaceuticals Limited ("BPL", "Beximco Pharma" or "Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces it has commenced the export of Carvedilol, a prescription drug for treating hypertension, to the US. This follows the product's approval from the US Food and Drug Administration ("US FDA") in November 2015 and is the first time a pharmaceutical product from Bangladesh has been launched in the US.
To mark the delivery of the first consignment on 4 August 2016, and to celebrate this milestone achievement for Beximco Pharma, a brief ceremony was held in the presence of Finance Minister, Mr. Abul Maal Abdul Muhith MP, Health and Family Welfare Minister, Mr. Mohammed Nasim MP and US Ambassador to Bangladesh Her Excellency Marcia Stephens Bloom Bernicat. Senior officials from different ministries, including the Export Promotion Bureau (EPB), the Federation of Bangladesh Chambers of Commerce and Industry (FBCCI) and the Bangladesh Association of Pharmaceutical Industries (BAPI) were also in attendance.
Commenting on the news, Beximco Group Vice Chairman Mr. Salman F Rahman said, "Today is a significant milestone for Beximco Pharma. As we deliver our first shipment of Carvedilol to the US market, we begin a new era for the pharmaceutical industry in Bangladesh. We believe our continued focus on building and strengthening the Group's presence in Western markets will cement Bangladesh's position as a major exporting country."
Beximco Pharma Managing Director Mr. Nazmul Hassan MP continued, "These initiatives are in line with our aspirations to expand our reach by taking products to the world. The US is the largest and most lucrative pharmaceutical market in the world. As a leading exporter of medicines, we always strive to capitalise on the generic drug opportunities in the world market. We believe our competitive products, especially with specialised and differentiated generic products, will help strengthen our presence in the US and other advanced markets."
Beximco Pharma became the first Bangladeshi pharmaceutical company audited and approved by the US FDA in June 2015.
Beximco Pharma is the largest exporter of pharmaceuticals in Bangladesh, winning the country's National Export Trophy (Gold) a record five times, the highest national accolade for export. The Company currently has a global footprint in more than 50 countries and has been accredited by a number of global regulatory authorities, including US FDA, AGES (EU), TGA Australia, Health Canada, GCC and TFDA.
For further information please visit www.beximcopharma.com or enquire to:
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, ext.20080
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Sean Wyndham-Quin
Tel: +44 (0)20 3368 3551 / 3555
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. Ensuring access to quality medicines is the powerful aspiration that motivates 3,000 employees of the Company.
Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in South East Asia, including Singapore, Taiwan, Malaysia, Indonesia, Philippines and Hong Kong; Africa, including South Africa, Mauritius, Kenya, Ghana, Ethiopia, Uganda and Nigeria; Central Asia, including Azerbaijan; Middle East, including Kuwait and Jordan; Pacific Island countries; Latin and Central American countries; Europe, including Austria, Germany and Romania; Australia etc.
This information is provided by RNS
The company news service from the London Stock Exchange|
|Company announced that scrip dividend is delayed this year until after the AGM, to be held before year end|
|I received the cash dividend but still waiting for stock dividend - normally slow but getting a bit stretched.(?) True long way from Dhaka ! But the stock is going up so worth a bit more.|
|Yep, just received mine, in my Hargreaves account.
|I've received the dividend in YouInvest today at a rate of USD 0.012717 per share and the a conversion to GBP at an exchange rate of 0.755333. However there seems to have been a 15% reduction for "tax". Does anyone know who the tax is being paid to?
Just to answer my own question:
This seems to suggest that dividend tax in Bangladesh is 20%
But there is a convention agreed between the UK and Bangladesh designed to avoid double taxation which seems to limit the tax to UK residents to 15% (+ any extra to the UK if you are a higher rate taxpayer perhaps?)
I wasn't meaning to sound impatient.
Just re-replying to a previous poster who had asked about when the bonus might be paid.
This has been a very slow burner for me, but has also been one of my best investments.
|They are notoriously slow but so far it always arrives. maybe cheaper sterling will result in increase in the payment if the the BDT now 103. Stock once went to 55p - mixed comments about this company in the past in particular the 'dormant' issue of fungibility with the parent stock but this GDR has been around some considerable time and the Company is probably the flagship of this country with which we are much engaged with. I am happy to hold.|